An observational study in Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1 and Phosphoglucomutase 1 Deficiency, sponsored by Centre Hospitalier Universitaire de Liege. Completed at 1 site in Belgium. Open to participants aged Up to 28 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Centre Hospitalier Universitaire de Liege · Observational
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions. With a simple blood test, rare genetic conditions can be easily detected, and the early start of transformative treatment will help avoid severe disabilities and increase the quality of life.
Baby Detect Project is an innovative NBS program using a panel of target sequencing that aims to identify 126 treatable severe early onset genetic diseases at birth caused by 361 genes. The list of diseases has been established in close collaboration with the Paediatricians of the University Hospital in Liege. The investigators use dedicated dried blood spots collected between the first day and 28 days of life of babies, after a consent sign by parents.
Every year, thousands of children around the world are born with rare genetic diseases leading to death or lifelong disability. With technological advancements in the field of genetics and medicine, the rate of introduction of treatments for these rare conditions has grown remarkably.
However, timing is of great importance for medication administration. The benefit that can be measured in a patient who has already suffered from a long irreversible degenerative disorder is small and, sometimes, it hardly justifies the cost and the burden of the treatment. Early diagnosis is, thus, of primary importance both to obtain the best effect of the innovative medications and to accelerate their development.
The investigators are pioneered in the field of genetic newborn screening (NBS) in rare diseases by funding, designing, and leading an innovative genetic NBS program initiated in March 2018 in Southern Belgium for Spinal Muscular Atrophy (SMA) that allowed, so far, for 11 children to be detected and treated early and avoid the terrible fate of the disease. The program was disseminated in 17 countries and included public dissemination and health-economic analysis since the very beginning [1]. (www.facebook.com/sunmayariseonsma).
Drawing upon our experience with SMA screening, the investigators have designed a project to screen up to 40,000 newborns/year progressively in 3 years for virtually all the rare diseases that can benefit from treatment or a pre-symptomatic clinical trial.
The methodology of Baby Detect includes sequencing of target genes on dried blood spots collected from the NBS cards in a timely and cost-efficient manner, and its high dynamicity allows for any newly treatable rare disease to be included in its scheme in no longer than 6 months.
Baby Detect, as a multidisciplinary newborn screening program, involves expertise in areas from genetics and medicine to laboratory studies, computer science, Data Protection, Ethics, and health economy. It will constitute the proof of concept that is needed before moving to a whole region-scale population.
101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.
This study's enrollment of 6,824 is above the median of 61 across 44 observational studies indexed under Adrenal Hyperplasia, Congenital.
Browse Adrenal Hyperplasia, Congenital studies →Centre Hospitalier Universitaire de Liege is the lead sponsor of 40 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Newborns whose mothers and/or the second-parents meet the inclusion criteria and have provided their consent to take part in the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Newborns with parent's consent
Acceptability
The percentage of parents accepting the proposed screening in comparison with the number of mothers approached for consent
Time frame: through study completion, an average of 1 year
Feasibility - timing
The Turn-around time for the different mutations that are screened
Time frame: through study completion, an average of 1 year
Feasibility - reliability
The percentage of false positives and the predicted value for each test The estimation of the false negatives through collaboration with physicians treating the different diseases.
Time frame: through study completion, an average of 1 year
Consequence of NBS on early treatment access - timing
The time passed between the birth of diagnostic-positive newborns to the initiation of their treatment
Time frame: through study completion, an average of 1 year
Consequence of NBS on early treatment access - frequency
The number of patients offered early treatment
Time frame: through study completion, an average of 1 year
To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants.
The number of new mutations implemented yearly in the NBS.
Time frame: through study completion, an average of 1 year
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adrenal Hyperplasia, Congenital →
Centre Hospitalier Universitaire de Liege